ArticleDrug design, development and therapy

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials.

Iulian Alecu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.